The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
Systemic sclerosis (SSc) is a rare autoimmune condition with complex pathogenesis characterized by a heterogeneous presentation and different disease courses. Fibrosis of multiple organs including the lungs favored by inflammation and vasculopathy is the hallmark of SSc. SSc-associated interstitial...
Main Authors: | Gonçalo Boleto, Jérôme Avouac, Yannick Allanore |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-01-01
|
Series: | Therapeutic Advances in Musculoskeletal Disease |
Online Access: | https://doi.org/10.1177/1759720X211066686 |
Similar Items
-
Targeting Costimulatory Pathways in Systemic Sclerosis
by: Gonçalo Boleto, et al.
Published: (2018-12-01) -
The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
by: Minrui Liang, et al.
Published: (2022-02-01) -
Interstitial lung diseases: the role of HRCT in in the era of antifibrotic therapy
by: Alfredo Nicodemos Cruz Santana, et al.
Published: (2020-11-01) -
Antifibrotic therapies in rheumatoid arthritis associated interstitial lung disease
by: Cemal Bes, et al.
Published: (2022-07-01) -
Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease
by: Erin M. Wilfong, et al.
Published: (2021-12-01)